Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 9/20 | 0.46 |
| ▸ | CDC25B | P30305 | 7/20 | 0.46 |
| ▸ | GJB2 | P29033 | 2/20 | 0.45 |
| ▸ | PTPN2 | P17706 | 4/20 | 0.45 |
| ▸ | PTPN11 | Q06124 | 4/20 | 0.45 |
| ▸ | PTPN6 | P29350 | 3/20 | 0.44 |
| ▸ | NT5E | P21589 | 1/20 | 0.44 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.43 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.43 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.43 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.43 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1775656 | 0.93 | PTPN1 (0.48) | SLC6A2PTPN1CDC25BGJB2PTPN2 | |
| SCHEMBL1776554 | 0.93 | PTPN1 (0.48) | SLC6A2PTPN1CDC25BGJB2PTPN2 | |
| SCHEMBL1775653 | 0.93 | PTPN1 (0.48) | SLC6A2PTPN1CDC25BGJB2PTPN2 | |
| SCHEMBL6379857 | 0.90 | GJB2 (0.50) | SLC6A2PTPN1CDC25BGJB2PTPN2 | |
| SCHEMBL8928604 | 0.90 | SSTR1 (0.48) | PTPN1CDC25BGJB2PTPN2PTPN11 | |
| SCHEMBL1775254 | 0.90 | SSTR1 (0.48) | PTPN1CDC25BGJB2PTPN2PTPN11 | |
| SCHEMBL9167095 | 0.90 | SSTR1 (0.48) | PTPN1CDC25BGJB2PTPN2PTPN11 | |
| SCHEMBL1775256 | 0.90 | SSTR1 (0.48) | PTPN1CDC25BGJB2PTPN2PTPN11 | |
| SCHEMBL13038862 | 0.90 | SSTR1 (0.48) | PTPN1CDC25BGJB2PTPN2PTPN11 | |
| SCHEMBL12920562 | 0.90 | SLC6A2 (0.54) | SLC6A2PTPN1CDC25BGJB2PTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160375120-A1 | SYNTHETIC OLIGOSACCHARIDES FOR MORAXELLA VACCINE | VISTERRA INC (US) | 2016-12-29 | — | — | US | disclosed |
| US-9447133-B2 | Synthetic oligosaccharides for moraxella vaccine | Visterra, Inc. (US) | 2016-09-20 | — | — | US | disclosed |
| US-20140148592-A1 | Synthetic Oligosaccharides for Moraxella Vaccine | Visterra, Inc. | 2014-05-29 | — | — | US | disclosed |
| US-8716469-B2 | Synthetic oligosaccharides for Moraxella vaccine | ANCORA PHARMACEUTICALS, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20130102759-A1 | Synthetic Oligosaccharides for Moraxella Vaccine | SYNGLYCO, INC. | 2013-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160375120-A1 | SYNTHETIC OLIGOSACCHARIDES FOR MORAXELLA VACCINE | FUT6, FUT5, MGAM | SLC6A2 4840/4885PTPN1 1234/4885CDC25B 2890/4885 |
| US-20130102759-A1 | Synthetic Oligosaccharides for Moraxella Vaccine | FUT6, OSTC, MGAM | SLC6A2 4837/4885PTPN1 1240/4885CDC25B 3276/4885 |
| US-20140148592-A1 | Synthetic Oligosaccharides for Moraxella Vaccine | FUT6, FUT5, MGAM | SLC6A2 4840/4885PTPN1 1234/4885CDC25B 2890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.